Pyronaridine is primarily used as an antimalarial agent, effective against Plasmodium species, including those resistant to other drugs like chloroquine. It is often combined with artesunate in artemisinin-based combination therapies (ACTs) to enhance efficacy and reduce the risk of drug resistance. This combination is particularly valuable in treating uncomplicated malaria in both adults and children. Additionally, pyronaridine has shown potential in treating other parasitic infections, though its use in these areas is still under research. Its broad-spectrum activity and relatively low toxicity make it a critical component in global efforts to combat malaria, especially in regions with high transmission rates.